{
    "address": "Grev Turegatan 11 C",
    "city": "Stockholm",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W72641108",
    "description": "Egetis Therapeutics AB engages in the development of new drugs for treatment of life-threatening diseases. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2011-04-07. The Company\u2019s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.",
    "employeeTotal": "10.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2011-04-07",
    "isin": "SE0003815604",
    "logo": "",
    "marketCapitalization": 935.9387,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Egetis Therapeutics AB (publ)",
    "phone": "4686797210.0",
    "sedol": "B4N7SB2",
    "shareOutstanding": 165.06856,
    "state": "STOCKHOLM",
    "ticker": "EGTX.ST",
    "weburl": "https://www.egetis.com/"
}